Method for prognosis prediction of skin cancer and use thereof

Patent metadata

Field	Value
Publication number	US-12578337-B2
Application number	US-202117918704-A
Country	US
Kind code	B2
Filing date	Apr 1, 2021
Priority date	Apr 15, 2020
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

Provided is a technique of predicting prognosis of skin cancer. A method for prognosis prediction of skin cancer includes: a step of obtaining a correlation amount correlated with an expression level of a glucose-6-phosphate dehydrogenase in a sample collected from a patient with the skin cancer; and a step of determining that the prognosis of the skin cancer is poorer when the correlation amount is large than that when the correlation amount is small.

First claim

The invention claimed is:

1 . A method of treating skin cancer in a patient, comprising determining the expression level of a glucose-6-phosphate dehydrogenase in a tumor sample collected from said patient by immunohistostaining of the sample, and administering an immune checkpoint inhibitor to said patient if the expression level of said glucose-6-phosphate dehydrogenase is determined by immunohistostaining of the sample to be less than 50% of the staining rate, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody or an anti-PD-1 antibody.

2 . The method of claim 1 , wherein said skin cancer is selected from the group consisting of Merkel cell carcinoma, malignant melanoma, squamous cell carcinoma, extramammary Paget disease, and cutaneous angiosarcoma.

3 . The method of claim 2 , wherein said skin cancer is Merkel cell carcinoma.

4 . The method of claim 1 , wherein the immunohistostaining of the sample is by visual observation of stained specimens under a microscope.

5 . The method of claim 1 , wherein said immune checkpoint inhibitor is Avelumab.

6 . A method of treating skin cancer in a patient, comprising determining the expression level of a glucose-6-phosphate dehydrogenase in a sample collected from said patient by immunohistostaining of the sample based on an antigen-antibody reaction using an anti-G6PD antibody or a fragment thereof, and administering an immune checkpoint inhibitor to said patient if the expression level of said glucose-6-phosphate dehydrogenase is determined by immunohistostaining of the sample to be less than 50% of the staining rate, wherein the skin cancer is selected from the group consisting of Merkel cell carcinoma, malignant melanoma, and cutaneous angiosarcoma, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody or an anti-PD-1 antibody.

7 . The method of claim 6 , wherein said immune checkpoint inhibitor is an anti-PD-L1 antibody.

8 . The method of claim 6 , wherein said immune checkpoint inhibitor is Avelumab.

9 . The method of claim 6 , wherein said skin cancer is Merkel cell carcinoma.

10 . The method of claim 6 , wherein said skin cancer is malignant melanoma.

11 . The method of claim 6 , wherein said skin cancer is cutaneous angiosarcoma.

Assignees

• Univ Nagoya City Public Univ Corp

Inventors

• Nakamura Motoki

Classifications

• G01N2333/904

  acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1) · CPC title

• G01N33/5011

  for testing antineoplastic activity · CPC title

• C12Y101/01049

  Glucose-6-phosphate dehydrogenase (1.1.1.49) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title